| Name | Title | Contact Details |
|---|
Alfa Aesar, a Johnson Matthey Company, is a leading international manufacturer and supplier of research chemicals, metals and materials. With 30,000 products listed in the catalogue, Alfa Aesar is the single source for customers' chemical and material
Frontier Scientific is a Logan, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Stratus Pharmaceuticals is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Azurity Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company focused on the needs of patients, especially children and the elderly, that require customized user-friendly drug formations. Our products have benefited millions of patients whose needs are not served by other commercially available therapies. AZURITY VALUES: COMPASSION - We put the needs of our patients and caregivers at the center of everything we do, including the decisions we make. QUALITY - We aim to provide our patients with the highest-quality, safe, and effective therapies for their needs. INNOVATION - We use the best science and manufacturing techniques to deliver cost-effective, high-value medications to our patients. A COMPANY OF DIFFERENCE MAKERS As Azurity grows to meet new challenges, and serve new patient groups, one thing never changes: our dedication to the lives of others. Whether through our innovative medications, our focus on creating a positive company environment, or our community and volunteer work, we are committed to having a positive impact on the lives of those we touch.
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company`s products are targeted at disease areas such as depression, schizophrenia, Parkinson`s disease and Alzheimer`s disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionised the treatment options, but there remains a large unmet need for new and innovative therapeutics. Focus on R&D is the most important pillar in Lundbeck`s ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have research facilities in Denmark and China, and more than 1,000 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions. Lundbeck employs approximately 5,300 people worldwide, 1,700 of whom are based in Denmark. We have employees in 55 countries, and our products are registered in more than 100 countries. We have production facilities in China, Denmark, France and Italy and research centres in Denmark and China.